Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women

Journal of Obstetrics and Gynaecology Research

Volumn 36, Issue 1, 2010, Pages 123-132

  Bhatla, Neerja ^a   Suri, Vanita ^b   Basu, Partha ^c   Shastri, Surendra ^d   Datta, Sanjoy K ^e   Bi, Dan ^e   Descamps, Dominique J ^e   Bock, Hans L ^e  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^d TATA MEMORIAL HOSPITAL   (India)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

AS04 adjuvanted; Cervical cancer; HPV 16 HPV 18; Immunogenicity; Seroconverted

Indexed keywords

ALUMINUM HYDROXIDE; CANCER VACCINE; PLACEBO; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD SAMPLING; BRADYCARDIA; CANCER IMMUNIZATION; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYPEREMIA; IMMUNOGENICITY; INDIAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RASH; SEROCONVERSION; URTICARIA; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INDIA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 76349117863     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2009.01167.x     Document Type: Article

References (44)

1. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006 24 : S311 S325.
2. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006 20 : 207 225.
3. Bhatla N, Lal N, Bao YP, Ng T, Qiao YL. A meta-analysis of human papillomavirus type-distribution in women from south Asia: Implications for vaccination. Vaccine 2008 26 : 2811 2817.
4. Sankaranarayanan R, Bhatla N, Gravitt PE et al. ICO monograph series on HPV and cervical cancer: Asia Pacific Regional Report. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine 2008 26 : M43 M52.
5. Murthy NS, Chaudhry K, Saxena S. Trends in cervical cancer incidence: Indian scenario. Eur J Cancer Prev 2005 14 : 513 518.
6. Vallikad E. Cervical cancer: the Indian perspective. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006 95 : S215 S233.
7. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. In IARC Cancer Base No. 5, version 2.0. Lyon : IARC Press, 2004.
8. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002 55 : 244 265. (Pubitemid 34293391)
9. Munoz N, Bosch FX, Sanjose SD et al., and the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 348 : 518 527. (Pubitemid 36159887)
10. Wallin KL, Wiklund F, Angstrom T et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999 341 : 1 6.
11. Bosch FX, De Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007 23 : 213 227.
12. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
13. Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004 111 : 278 285.
14. Pedersen C, Petaja T, Strauss G et al., HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007 40 : 564 571.
15. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007 121 : 621 632.
16. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human Papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003 88 : 63 73.
17. Bosch FX, Burchell AN, Schiffman M et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008 26 : K1 K16.
18. Bhatla N, Dar L, Rajkumar Patro A et al. Human papillomavirus-type distribution in women with and without cervical neoplasia in North India. Int J Gynecol Pathol 2008 27 : 426 432.
19. Franceschi S, Rajkumar T, Vaccarella S et al. Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer 2003 107 : 127 133.
20. Dabash R, Vajpayee J, Jacob M et al. A strategic assessment of cervical cancer prevention and treatment services in 3 districts of Uttar Pradesh, India. Reprod Health 2005 2 : 11.
21. Das BC, Hussain S, Nasare V, Bharadwaj M. Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 2008 26 : 2669 2679.
22. Ghim SJ, Basu PS, Jenson A. Cervical cancer: etiology, pathogenesis, treatment, and future vaccines. Asian Pac J Cancer Prev 2002 3 : 207 214.
23. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008 110 : S1 S10.
24. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 356 : 1915 1927.
25. Paavonen J, Jenkins D, Bosch FX et al., HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 369 : 2161 2170.
26. Schwarz TF. Human papillomavirus-16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer. Expert Rev Obstet Gynecol 2007 2 : 293 303.
27. Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer 2007 96 : 1320 1323.
28. Perez G, Lazcano-Ponce E, Hernandez-Avila M et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 2008 122 : 1311 1318.
29. Human D, Fluss Sev S. The World Medical Association's Declaration of Helsinki: historical and contemporary perspectives. 5th draft. 2001 [Cited 12 May 2009.] Available from URL: http://www.wma.net/en/20activities/10ethics/ 10helsinki/draft-historical-contemporary-perspectives.pdf
30. Central Drugs Standard Control Organisation. Good Clinical Practices for Clinical Research Cited 12 May 2009.] Available from URL: http://www.cdsco.nic. in/html/gcp.htm
31. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 2008 68 : 359 372.
32. Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009 374 : 301 314.
33. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008 110 : S18 S25.
34. Harper DM, Franco EL, Wheeler CM et al., HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006 367 : 1247 1255.
35. TM (GSK's HPV 16/18 AS04 candidate vaccine). Gynecol Oncol 2008 109 : 158 159 Late-breaking abstracts presented for the Thirty-Ninth Annual Meeting of the Society of Gynecologic Oncologists).
36. Schwarz TF, Spaczynski M, Schneider A et al., on behalf of the HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009 27 : 581 587.
37. Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006 24 : S3/106 S3/113.
38. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007 370 : 890 907.
39. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006 24 : 5937 5949.
40. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccine 2009 5 : 705 719.
41. The GlaxoSmithKline vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009 374 : 1975 1985.
42. David MP, Herck KV, Hardt K et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 2009 doi:10.1016/j.ygyno.2009.01.011.
43. Harper DM, Franco EL, Wheeler C et al., and the GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004 364 : 1757 1765.
44. Diaz M, Kim JJ, Albero G et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008 99 : 230 238.